A phase II open-label, 2-cohort study of nimotuzumab 400 mg weekly plus irinotecan (cohort 1) and nimotuzumab 400 mg every 2 weeks plus irinotecan (cohort 2) in patients with irinotecan-refractory metastatic colorectal cancer

Trial Profile

A phase II open-label, 2-cohort study of nimotuzumab 400 mg weekly plus irinotecan (cohort 1) and nimotuzumab 400 mg every 2 weeks plus irinotecan (cohort 2) in patients with irinotecan-refractory metastatic colorectal cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2009

At a glance

  • Drugs Irinotecan; Nimotuzumab
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors YM BioSciences
  • Most Recent Events

    • 16 Nov 2008 Status changed from active, no longer recruiting to discontinued, as reported in ClinicalTrials.gov record, which cited "Cohort 2 not going forward. Manadate changes in Company"
    • 04 Aug 2008 Interim results reported in a YM Biosciences media release.
    • 21 Jul 2008 Mechanism of action data presented at the AACR Conference on Translational Cancer Medicine 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top